Summary
On March 31, 2026, a director of RH executed a block of sales totaling 11,000 shares of common stock for about $1.5 million, with trade prices spanning $135.2726 to $140.0203. The director simultaneously exercised options to purchase 11,000 RH shares at $39.42, a transaction valued at $433,620. The sales were carried out under a Rule 10b5-1 trading plan adopted on October 7, 2024. Following these transactions the director holds no RH shares directly, but retains an indirect stake of 23,643 shares through the Chaya-Smith Revocable Trust.
Details of the insider activity
The reported divestiture comprised multiple transactions executed on March 31, 2026, with executed prices ranging from $135.2726 to $140.0203 and aggregate proceeds of approximately $1.5 million. In conjunction with the sale, the director exercised options to acquire an equal number of common shares - 11,000 - at a strike price of $39.42, resulting in a cost basis of $433,620 for those newly acquired shares.
After the trading and option exercise, the director no longer holds RH stock directly. Indirect ownership remains via the Chaya-Smith Revocable Trust, which holds 23,643 shares. The sales were pre-scheduled under a Rule 10b5-1 plan that was adopted on October 7, 2024.
Market context
RH shares have fallen 54.7% over the last year and are trading close to their 52-week low of $106.30. Despite the recent price weakness, an InvestingPro analysis cited in connection with this activity indicates that RH may still be undervalued, with further analysis available through subscriber-only ProTips.
Analyst reactions following RH’s latest results
Several brokerages have revised their views and price targets in the wake of RH’s fourth-quarter fiscal 2025 results and fiscal 2026 guidance.
- Stifel reduced its price target from $133 to $110 while keeping a Hold rating.
- TD Cowen lowered its target to $170 from $200, citing a weaker fourth quarter and fiscal 2026 guidance that fell below most forecasts.
- BNP Paribas Exane cut its target to $96 from $130 and maintained an Underperform rating, citing concerns about the company’s growth strategy and debt load.
- Telsey Advisory Group trimmed its price objective to $140 from $165, pointing to headwinds in the housing market and the necessity for continued investment in international growth.
- William Blair kept a Market Perform rating, observing that RH’s shares have underperformed peers even as the company has outlined plans for growth and margin expansion from 2027 to 2030.
These analyst adjustments reflect a range of concerns referenced by the firms, including recent operating results, forward guidance, strategic execution and leverage, as RH navigates market conditions while pursuing longer-term growth and margin targets.
What this means
The insider sale, coordinated through an established 10b5-1 plan, and the option exercise leave the director without direct holdings while preserving an indirect stake via a trust. Concurrently, the string of analyst target reductions and ratings updates underscores investor scrutiny around RH’s near-term performance, strategic direction and balance sheet considerations.